GDF2026 - ICH M13A High-Risk vs. Low-Risk Case Studies – Bioequivalence (BE) Implications
Regulatory presentation (FDA-related) · July 30, 2026
Agency official presented ICH M13A guidance and explained FDA risk-classification for bioequivalence (BE) studies, illustrating how high-risk vs. non-high-risk designations change BE study recommendations through three mock ANDA case studies.
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
No transcript available.
No outline available for this source.
No related articles available for this source.
No highlights available for this source.
No claims available for this source.
No actions available for this source.
No topics available for this source.
No clarifying details available for this source.
No discussions available for this source.
No community relevance data available for this source.
No funding sources available for this source.
No speakers available for this source.
No transcript available for this source.